泰莎基因治疗公司（纳斯达克代码：TSHA）公布其季度每股亏损$(0.07)，优于分析师一致预期的$(0.08)，超出预期12.5%。与去年同期每股收益$0.92相比，本次为107.61%的下降。公司报告季度销售额为$202万，低于分析师预期的$231万，差距为12.43%。此外，与去年同期$360万的销售额相比，本季度销售额下降了43.90%。

以上内容来自Benzinga Earnings专栏，原文如下：

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 107.61 percent decrease over earnings of $0.92 per share from the same period last year. The company reported quarterly sales of $2.02 million which missed the analyst consensus estimate of $2.31 million by 12.43 percent. This is a 43.90 percent decrease over sales of $3.60 million the same period last year.